Lung Cancer 10 Suppl. l(1994) Sl

Introduction

During the last decade, lung cancer has become the major cause of death among adult malignancies in the Western countries. The treatment of choice is surgery when the disease is operable. Adjuvant treatments including chemotherapy and radiotherapy have been actively evaluated in this subset of patients without a clear conclusion about their effectiveness. Similarly, combined therapies in locally ad- vanced tumors have not unequivocally proved to be superior to a single treatment modality. The First Workshop on Combined Modalities held in Le Havre in 1987 (Treatment modalities in lung cancer. In: R. Arriagada, T. Le Chevalier, editors. Antibiotics and chemotherapy. Basel: Karger Publish., 1988; 41: 248 p.) concluded in the interest to pursue the evaluation of such adjuvant therapies. It appeared important to us to redefine the ‘state of the art’ 5 years later and this was the main objective of the Fontainebleau Workshop.

We are very grateful to all participants who allowed to induce exciting discus- sions and to define new areas of consensus and controversies to be investigated in the next years.

This IASLC Workshop was organized with the generous help of Amgen Roche, Aries Groupe Fiteg, Association pour la Recherche Therapeutique sur le Cancer Bronchique (R.C.P.), Asta Medica, Bristol-Myers Squibb USA, Bristol-Myers Squibb France, Cis Bio International, Farmitalia-Carlo Erba, International Associ- ation for the Study of Lung Cancer (IASLC), Institut de Recherches Internatio- nales Servier (I.R.I.S.), Institut Gustave-Roussy, Laboratoires Sarget, Laboratoires Lederle France, Laboratoires Lilly France, Laboratoire Pierre Fabre Oncologic, Laboratoires Roger Bellon.

0169-5002/94~‘$07.00 G3 1994 Elsevier Science Ireland Ltd. All rights reserved. SSDI Olh9-S002(93W)025h-Z